Eris Lifesciences Limited was incorporated on January 25 2007. Subsequently the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9 2007. Further the company was converted into a public limited company and the name was changed to 'Eris Lifesciences Limited' on February 2 2017. The company develops manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM) such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. As on 31 March 2019 the Company has 5 subsidiaries of which 4 are wholly owned subsidiaries.In 2007 the company launched 'Eris' division focused on cardiology and diabetes segment. In 2008 the company launched 'Nikkos' division focused on gastroenterology and orthopedics segment. In 2009 the company launched 'Adura' division focused on cardiology and diabetes segment. In 2011 the company launched 'Montana' division focused on gynecology and pediatrics segment. In 2012 the company launched 'Inspira' division focused on cardiology segment. In 2014 the company launched 'Victus' division focused on anti-diabetes segment. During the year the company set up manufacturing facility at Assam. In 2015 the company launched 'Eris 2' division focused on pain management segment.In 2016 the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now Aprica Pharmaceuticals Private Limited). During the year the company acquired 100% of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited. In 2017 the company acquired the trademarks `UNION' `REUNION' and `BON UNION'.Eris Lifesciences made its debut on the secondary equity market on 29 June 2017. The stock debuted at Rs 612 on BSE compared with the initial public offer (IPO) price of Rs 603.In October 2017 Eris Lifesciences Ltd (Eris) acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an all-cash consideration of Rs 129 million. UTH is largely engaged in the segments of obesity diabetes gestational diabetes mellitus maternal nutrition and cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.In December 2017 Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of Rs 5000 crore. With this acquisition Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology Psychiatry Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017.During the year 2018 capital expenditure amounted to Rs 242.69 million. Additionally consideration of Rs. 5061.52 million was paid towards business acquisition.During the year 2018 UTH Healthcare Limited and Eris Healthcare Private Limited (earlier known as Strides Healthcare Private Limited) became subsidiaries of the Company.During the year 2019 capital expenditure amounted to Rs 374.15 million. Additionally consideration of Rs. 107.22 million was paid towards business acquisition.In April 2019 the Company acquired the remaining shares of Kinedex Healthcare Private Limited thereby making it a wholly owned subsidiary.